ArticleBMC genomics2011
The genome sequence of E. coli W (ATCC 9637): comparative genome analysis and an improved genome-scale reconstruction of E. coli.
Article in BMC genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed.
- Transcriptional regulatory network differences between six industrialMetabolic engineering communications · 2026Article
- The Effects of Exogenous Glutathione on β-lactam Susceptibility in New Delhi Metallo-β-Lactamase (NDM-1) Producing Klebsiella pneumoniae.Current microbiology · 2026Article
- CRISPR-Mediated Metabolic Engineering ofMicroorganisms · 2026Article
- Detection of Spoilage-Associated Acetic Acid Levels Using a Transcription-Based Whole-Cell Biosensor.Microbial biotechnology · 2025Article
- The physiological functions of the Cbp2D and Cbp2E proteins are important for insoluble cellulose-dependent growth inApplied and environmental microbiology · 2025Article
- Engineering a Robust Escherichia coli W Platform for Scalable Production of Flavonoid-O-Glucosides.Microbial biotechnology · 2025Article
- Use of genome-scale metabolic reconstructions of avian pathogenicMicrobial genomics · 2025Article
- Experimental evolution ofMicrobiology spectrum · 2025Article
- Tailoring Escherichia coli BL21 (DE3) for preferential xylose utilization via metabolic and regulatory engineering.Applied microbiology and biotechnology · 2025Article
- CyuR is a dual regulator for L-cysteine dependent antimicrobial resistance in Escherichia coli.Communications biology · 2024Article
- Synthetic redesign of Escherichia coli W for faster metabolism of sugarcane molasses.Microbial cell factories · 2024Article
- Citrate synthase variants improve yield of acetyl-CoA derived 3-hydroxybutyrate in Escherichia coli.Microbial cell factories · 2024Article
- Toxin-based screening of C-terminal tags inbioRxiv : the preprint server for biology · 2024Article
- A validated pangenome-scale metabolic model for theMicrobial genomics · 2024Article
- A computational model of Pseudomonas syringae metabolism unveils a role for branched-chain amino acids in Arabidopsis leaf colonization.PLoS computational biology · 2023Article
- Safety of 2'-fucosyllactose (2'-FL) produced by a derivative strain (EFSA journal. European Food Safety Authority · 2023Article
- Safety of 3'-sialyllactose (3'-SL) sodium salt produced by a derivative strain (EFSA journal. European Food Safety Authority · 2023Article
- Evaluation of VariousJournal of microbiology and biotechnology · 2023Article
- Safety of 6'-sialyllactose (6'-SL) sodium salt produced by a derivative strain (EFSA journal. European Food Safety Authority · 2023Article
- Predicting partner fitness based on spatial structuring in a light-driven microbial community.PLoS computational biology · 2023Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEscherichia coli is a model prokaryote, an important pathogen, and a key organism for industrial biotechnology. E. coli W (ATCC 9637), one of four strains designated as safe for laboratory purposes, has not been sequenced. E. coli W is a fast-growing strain and is the only safe strain that can utilize sucrose as a carbon source. Lifecycle analysis has demonstrated that sucrose from sugarcane is a preferred carbon source for industrial bioprocesses.
resultsWe have sequenced and annotated the genome of E. coli W. The chromosome is 4,900,968 bp and encodes 4,764 ORFs. Two plasmids, pRK1 (102,536 bp) and pRK2 (5,360 bp), are also present. W has unique features relative to other sequenced laboratory strains (K-12, B and Crooks): it has a larger genome and belongs to phylogroup B1 rather than A. W also grows on a much broader range of carbon sources than does K-12. A genome-scale reconstruction was developed and validated in order to interrogate metabolic properties.
conclusionsThe genome of W is more similar to commensal and pathogenic B1 strains than phylogroup A strains, and therefore has greater utility for comparative analyses with these strains. W should therefore be the strain of choice, or 'type strain' for group B1 comparative analyses. The genome annotation and tools created here are expected to allow further utilization and development of E. coli W as an industrial organism for sucrose-based bioprocesses. Refinements in our E. coli metabolic reconstruction allow it to more accurately define E. coli metabolism relative to previous models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.